COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, Hanneke Oude Elberink, Cem Akin, Boguslaw Nedoszytko, Joseph H. Butterfield, Ivan Alvarez-Twose, Karl Sotlar, Juliana Schwaab, Mohamad Jawhar, Mariana Castells, Wolfgang R. Sperr, Olivier Hermine, Jason Gotlib, Roberta Zanotti, Andreas Reiter, Sigurd Broesby-Olsen, Carsten Bindslev-Jensen, Lawrence B. SchwartzHans Peter Horny, Deepti Radia, Massimo Triggiani, Vito Sabato, Melody C. Carter, Frank Siebenhaar, Alberto Orfao, Clive Grattan, Dean D. Metcalfe, Michel Arock, Theo Gulen, Karin Hartmann, Peter Valent

Research output: Contribution to journalReview articlepeer-review

30 Scopus citations

Abstract

Mastocytosis is a neoplasm characterized by an accumulation of mast cells in various organs and increased risk for severe anaphylaxis in patients with concomitant allergies. Coronavirus disease 2019 (COVID-19) is a pandemic that is associated with a relatively high rate of severe lung disease and mortality. The mortality is particularly high in those with certain comorbidities and increases with age. Recently, several companies have developed an effective vaccination against COVID-19. Although the reported frequency of severe side effects is low, there is an emerging discussion about the safety of COVID-19 vaccination in patients with severe allergies and mastocytosis. However, even in these patients, severe adverse reactions are rare. We therefore recommend the broad use of COVID-19 vaccination in patients with mastocytosis on a global basis. The only well-established exception is a known or suspected allergy against a constituent of the vaccine. Safety measures, including premedication and postvaccination observation, should be considered in all patients with mastocytosis, depending on the individual personal risk and overall situation in each case. The current article provides a summary of published data, observations, and expert opinion that form the basis of these recommendations.

Original languageEnglish
Pages (from-to)2139-2144
Number of pages6
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume9
Issue number6
DOIs
StatePublished - Jun 2021
Externally publishedYes

Keywords

  • Adverse reaction to medications
  • COVID-19
  • Hypersensitivity reactions
  • Mast cell diseases
  • Mastocytosis
  • Vaccine

Fingerprint

Dive into the research topics of 'COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)'. Together they form a unique fingerprint.

Cite this